BIOALVO S.A.

BIOALVO is the first Portuguese biotech company working on early stages of drug discovery. BIOALVO designs and develops innovative drug discovery and development programmes that generate potent and efficient drugs aimed at central nervous system and neurodegenerative disorders. Through its proprietary innovative platforms BIOALVO can accelerate and increase the efficiency of drug discovery through HTS and generate true and potent drug candidates for its pipeline and of its partners that will ultimately lead to treatments and cures for human diseases with dramatic social impacts such as amyloidosis, Huntington’s, Alzheimer’s, Parkinson’s or cancer. The company operates an alliance-based R&D business model establishing partnership to fill its pipeline and potentiate its partner’s assets, bringing products and solutions to the market. BIOALVO is fully committed in building value by developing a diverse pipeline of products to address unmet healthcare needs.